Progress in understanding melanoma propagation.

Molecular Oncology
Mark Shackleton, Elsa Quintana

Abstract

Melanoma, like most cancers, is a disease that wreaks havoc mostly through its propensity to spread and establish secondary tumors at sites that are anatomically distant from the primary tumor. The consideration of models of cancer progression is therefore important to understand the essence of this disease. Previous work has suggested that melanoma may propagate according to a cancer stem cell (CSC) model in which rare tumorigenic and bulk non-tumorigenic cells are organized into stable hierarchies within tumors. However, recent studies using assays that are more permissive for revealing tumorigenic potential indicate that it will not be possible to cure patients by focusing research and therapy on rare populations of cells within melanoma tumors. Studies of the nature of tumorigenic melanoma cells reveal that these cells may gain a growth, metastasis and/or therapy resistance advantage by acquiring new genetic mutations and by reversible epigenetic mechanisms. In this light, efforts to link the phenotypes, genotypes and epigenotypes of melanoma cells with differences in their in vivo malignant potential provide the greatest hope of advancing the exciting progress finally being made against this disease.

References

Oct 1, 1976·Science·P C Nowell
Jun 1, 1990·Cell·E R Fearon, B Vogelstein
Jan 1, 1999·Nature·C LengauerB Vogelstein
Mar 4, 2000·International Journal of Cancer. Journal International Du Cancer·M TakataK Takehara
Nov 2, 2001·Nature·T ReyaI L Weissman
Jun 18, 2002·Nature·Helen DaviesP Andrew Futreal
Jul 1, 1958·Journal of Chronic Diseases·L FOULDS
Sep 3, 2004·The New England Journal of Medicine·Hensin TsaoArthur J Sober
Nov 19, 2004·Nature·Sheila K SinghPeter B Dirks
Dec 24, 2004·The New England Journal of Medicine·Vincenzo de GiorgiBenvenuto Giannotti
Feb 25, 2005·Springer Seminars in Immunopathology·Morgan E Wallace, Mark J Smyth
May 10, 2005·The Journal of Immunology : Official Journal of the American Association of Immunologists·Leonard D ShultzRupert Handgretinger
Oct 19, 2005·Cancer Research·Dong FangMeenhard Herlyn
Nov 24, 2006·Nature·Lucia Ricci-VitianiRuggero De Maria
Jan 4, 2007·The British Journal of Dermatology·S C WeatherheadC M Lawrence
Feb 27, 2007·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Elena MonzaniCaterina A M La Porta
Jun 16, 2007·Nature Reviews. Immunology·Yong-Guang Yang, Megan Sykes
Jul 21, 2007·Science·Priscilla N KellyAndreas Strasser
Jul 25, 2007·Annual Review of Cell and Developmental Biology·Neethan A LoboMichael F Clarke
Sep 1, 2007·Genes & Development·Richard T WilliamsCharles J Sherr
Dec 15, 2007·Science·James A KennedyJohn E Dick
Jan 19, 2008·Nature·Tobias SchattonMarkus H Frank
Feb 5, 2008·Cancer Research·Keith S HoekReinhard Dummer
Feb 12, 2008·Nature·Stacey L EdwardsAlan Ashworth
Apr 11, 2008·Journal of Cutaneous Pathology·Steven J OhsieScott W Binder
May 3, 2008·Cancer Research·I Bernard Weinstein, Andrew Joe
Dec 5, 2008·Nature·Elsa QuintanaSean J Morrison
Dec 10, 2008·Blood·John E Dick
Feb 18, 2009·Cancer Immunology, Immunotherapy : CII·Craig GedyeIan D Davis
Sep 8, 2009·Nature Medicine·Piyush B GuptaRobert A Weinberg
Sep 10, 2009·Cell·Mark ShackletonSean J Morrison
Nov 17, 2009·Proceedings of the National Academy of Sciences of the United States of America·Caroline M EmeryLevi A Garraway
Nov 26, 2009·Biochimica Et Biophysica Acta·Andriy Marusyk, Kornelia Polyak
Dec 1, 2009·Cancer Letters·Yong ZhongShuren Zhang
Jan 6, 2010·Cancer Research·Matthew A HeldMarcus W Bosenberg
May 4, 2010·Seminars in Cancer Biology·Mark Shackleton

❮ Previous
Next ❯

Citations

Aug 14, 2010·Pigment Cell & Melanoma Research·Mark Shackleton
Oct 19, 2011·Pigment Cell & Melanoma Research·Rachel E Bell, Carmit Levy
Feb 18, 2012·Pigment Cell & Melanoma Research·Daniel S WidmerKeith S Hoek
Mar 6, 2012·Seminars in Radiation Oncology·Thomas B BrunnerMichael Baumann
Aug 18, 2012·The Journal of Pathology·Philipp Grosse-GehlingLeoni A Kunz-Schughart
Feb 26, 2013·Pigment Cell & Melanoma Research·Jacky BonaventureLionel Larue
Dec 7, 2011·Critical Reviews in Clinical Laboratory Sciences·Miguel AsensiJosé M Estrela
Aug 10, 2010·Molecular Oncology·Jane E Visvader, Geoffrey J Lindeman
Mar 26, 2014·Integrative Biology : Quantitative Biosciences From Nano to Macro·X LiangF H Labeed
Apr 25, 2015·Revista da Associação Médica Brasileira·Natália Cristina Ciufa Kobayashi, Samuel Marcos Ribeiro de Noronha
Mar 8, 2011·Oncotarget·Jiabo DiRuurd Torensma

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.